Cargando…
New perspectives for the treatment of pulmonary hypertension
Pulmonary hypertension (PH) is a debilitating disease with a poor prognosis. Therapeutic options remain limited despite the introduction of prostacyclin analogues, endothelin receptor antagonists and phosphodiesterase 5 inhibitors within the last 15 years; these interventions address predominantly t...
Autores principales: | Baliga, Reshma S, MacAllister, Raymond J, Hobbs, Adrian J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085874/ https://www.ncbi.nlm.nih.gov/pubmed/21175577 http://dx.doi.org/10.1111/j.1476-5381.2010.01164.x |
Ejemplares similares
-
Manipulating the natriuretic peptide system for the treatment of pulmonary hypertension
por: Baliga, Reshma S, et al.
Publicado: (2009) -
Enhancing natriuretic peptide bioactivity prevents bleomycin-induced pulmonary fibrosis
por: Baliga, Reshma S, et al.
Publicado: (2011) -
Intrinsic defence capacity and therapeutic potential of natriuretic peptides in pulmonary hypertension associated with lung fibrosis
por: Baliga, R S, et al.
Publicado: (2014) -
Clinical applications of remote ischaemic preconditioning in native and transplant acute kidney injury
por: Veighey, Kristin, et al.
Publicado: (2014) -
Clinical Applications of Remote Ischemic Preconditioning
por: Veighey, Kristin, et al.
Publicado: (2012)